AUTHORS
Evangelos Terpos, MD, Maria Gavriatopoulou, MD2, Ioannis Ntanasis-Stathopoulos, MD3, Panagiotis Malandrakis, MD, MSc, PhD4, Nikolaos Kanellias, MD, PhD5, Yagnik Vyas6, Magdalini Migkou7, Foteini Theodorakakou, MD8, Eirini Solia, MD9, Evangelos Eleutherakis-Papaiakovou10, Efstathios Kastritis, MD11, Meletios-Athanasios (Thanos) C. Dimopoulos, MD12
AFFILIATIONS
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 Veeda Lifesciences, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 Korea University, Seoul, Korea, Rep. of South, National and Kapodistrian University of Athens, Athens, Greece
ABSTRACT
Introduction The aim of this study was to evaluate safety, tolerability, and clinical activity of belamaf plus lenalidomide and dexamethasone (Rd) (BelaRd) in transplant ineligible newly diagnosed multiple myeloma (TI-NDMM) patients (pts). In this abstract we focus on the safety of BelaRd in this population and explore whether routine pre-dose ophthalmic examinations can be reduced or potentially eliminated in pts receiving belamaf.
Methods BelaRd trial (NCT04808037) was a phase 1/2, open label study in frail and intermediate-fit pts with NDMM. In Part 2, n=30 pts were treated at recommended part 2 dose (RP2D) of 1.9mg/kg derived from part 1. The safety and efficacy of the RP2D were evaluated in two randomized cohorts (Groups A and B; n = 15 each). The study also compared two strategies for managing ocular adverse events (OAEs). In Group A, belamaf dose modifications were guided by the Keratopathy and Visual Acuity (KVA) scale assessed by an opthalmologist. In Group B, dose modifications were based on patients' Vision-Related Anamnestic (VRA) questionnaire responses, which assessed ocular symptoms and their impact on activities of daily living (ADL); this questionnaire was evaluated by the treating hematologist. All patients of group B were also checked by an ophthalmologist and in case of the presence of ≥Grade 3 KVA events (reduced best-corrected visual acuity [BCVA] and/or corneal findings), the ophthalmologist decision was taken into account irrespective of the hematologist decision.
Results At the clinical data cut-off (15th May 2026), 19 of 30 patients (63.3%) in Part 2 were still receiving treatment. At baseline, ECOG PS was 1/2 in 56.7%/3.3%; R-ISS staging was II/III in 63.3%/10% and high-risk cytogenetics was present in 16.7% of pts. At baseline cataract was observed in 86.7% (26/30) pts; (14 (93.3%) in Gr A and 12 (80%) in Gr B). Overall response rate (ORR) (≥PR) was 96.7% in part 2 (sCR, 53.3%; CR, 3.3%; VGPR, 30%; and PR, 10%). Dose holds due to OAEs occurred in 22.7% of planned doses in Gr A (KVA) versus 2.7% in Gr B (VRA). Grade ≥3 OAEs without VRA-reported “substantial time” (>50% of total time) were detected in 7/354 (1.9%) (total number of assessments) and 2/168 (1.2%) (total number of dosing cycle) in Gr B. Grade ≥3 BCVA deterioration and keratopathy was observed in 7.6% (34/447) and 5.9% (21/354) of ophthalmologist assessments in Gr A and B, respectively. The median time to resolution of Grade ≥2 keratopathy and BCVA ocular events was 1.8 months (range 0.9-14.9) in Gr A and 1.2 months (range 0.9-3.7) in Gr B. In part 2 overall, the absence of patient reported blurry or poor vision on the VRA was associated with low frequency of Grade ≥2 keratopathy (6/351 (1.7%) and 2/243 (0.8%) of assessments, respectively and no grade ≥3 Keratopathy was observed among patients reporting no blurry or poor vision on the VRA. The absence of patient reported blurry or poor vision on the VRA Grade ≥2 BCVA was 33/351 (9.4%) and 19/243 (7.8%) of assessments and Grade ≥3 was 1/351 (0.2%) and none, respectively. Driving/reading discontinuation due to eyesight issues occurred in 0.5%/0.6% of monthly assessments in Gr B and 0.0%/0.2%in Gr A.
Conclusion The VRA tool was safe and effective for guiding belamaf dose modifications. VRA and KVA assessments were highly concordant, with patients reporting no ocular symptoms on the VRA experiencing <10% of Grade ≥2 OAEs and only 0.2% Grade ≥3 OAEs. Compared with KVA-guided dosing, VRA-guided dosing was associated with favorable ocular safety, fewer OAEs and dose holds, and faster resolution of ocular events.
These findings support further evaluation of the VRA as a dosing-guidance tool and suggest that its use may reduce or potentially eliminate the need for routine pre-dose ophthalmic examinations in patients receiving belamaf.
Funding by GSK (NCT04808037); authors solely responsible for content.
DISCLOSURES
Evangelos Terpos, MD: Swixx - Honoraria; Takeda - Honoraria; Menarini - Honoraria; Johnson & Johnson - Honoraria; Sanofi - Honoraria; GSK - Honoraria; Forus - Honoraria; Bristol Myers Squibb - Honoraria; Antengene - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; EUSA Pharma - Honoraria; Johnson & Johnson - Research Funding; GSK - Research Funding; Sanofi - Research Funding; Menarini - Research Funding; Menarini - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)